top of page

Administrative information

Open Science

Introduction

Methods: Patient and public involvement, trial design

Methods: Participants, interventions, and outcomes

Methods: Assignment of interventions

Methods: Data collection, management, and analysis

Methods: Monitoring

Ethics

Sequence generation

Item 21b: Type of randomisation (simple or restricted) and details of any factors for stratification. To reduce predictability of a random sequence, other details of any planned restriction (e.g., blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions.

Example

 

“On the day of surgery, participants will be randomized (1:1) to one of two treatment arms. Randomization will be stratified by hernia width measured during the procedure using the European Hernia Society Width categories (W1 <4cm, W2 4-10cm, W3 >10cm) [reference] to ensure equitable distribution of disease severity between the two treatment arms. ... The block sizes will not be known to the PIs. Randomization will take place through the Research Electronic Data Capture (REDCap™) system [reference]" [332]

“Participants will be randomly assigned to either control or experimental group with a 1:1 allocation as per a computer generated randomisation schedule stratified by site and the baseline score of the Action Arm Research Test (ARAT; <= 21 versus >21) using permuted blocks of random sizes. The block sizes will not be disclosed, to ensure concealment [333].

Explanation

 

Trial protocols must address the type of randomisation planned (Box 4), as this is the defining feature of a randomised trial. If stratification will be used, the stratification categories (including relevant cut-off boundaries) should be reported (e.g., recruitment site, sex, disease stage).

 

When restricted randomisation is planned, details on restriction (including minimisation) should not appear in the main body of the protocol in order to reduce predictability of the random sequence (Box 5). The details should instead be described in a separate document that is unavailable to trial implementers, such as recruiters, screeners, enrolers, and assigners. For blocked randomisation, this information would include details on how the blocks will be generated (e.g., permuted blocks by a computer random number generator), the block size(s), and whether the block size will be fixed or randomly varied.

 

Simple randomisation (unrestricted randomisation) can be specified in the main body of the protocol because it is perfectly unpredictable. Its use does not require a separate document.

Box 4 Randomisation and minimisation

 

Simple randomisation

Randomisation based solely on a single, constant allocation ratio is known as simple randomisation [324, 334, 335] Simple randomisation with a 1:1 allocation ratio is analogous to an unbiased coin toss, although tossing a coin is not recommended for sequence generation. No other allocation approach, regardless of its real or supposed sophistication, surpasses the bias prevention and unpredictability of simple randomisation [322, 335].

Restricted randomisation

Any randomised approach that is not simple randomisation is restricted. Blocked randomisation is the most common form. Other forms, used much less frequently, are methods such as replacement randomisation, biased coin, and urn randomisation [322, 335].

Blocked randomisation

Blocked randomisation (also called permuted block randomisation) assures that study groups of approximately the same size will be generated when an allocation ratio of 1:1 is used. Blocking can also ensure close balance of the numbers in each group. After every block of 8 participants, for example, 4 would have been allocated to each trial group [336] Improved balance comes at the cost of reducing the unpredictability of the sequence. Although the order of interventions varies randomly within each block, a person running the trial could deduce some of the next treatment allocations if they discovered the block size [337]. Blinding the interventions, using larger block sizes, and randomly varying the block size will help to avoid this problem [322]. Fixed blocks of 2 or 4 are most problematic, as allocation may become predictable for a sizeable proportion of trial participants.

 

Biased-coin and urn randomisation

Biased-coin designs attain the similar objective as blocked designs without forcing strict equality. They therefore preserve much of the unpredictability associated with simple randomisation. Biased-coin designs alter the allocation ratio during the course of the trial to rectify imbalances that might be occurring [322, 335]. Adaptive biased-coin designs, such as the urn design, vary allocation ratios based on the magnitude of the imbalance. However, these approaches are used infrequently.

 

Stratified randomisation

Stratification is used to ensure good balance of participant characteristics in each group. Without stratification, study groups may not be well matched for baseline characteristics, such as age and stage of disease, especially in small trials. Such imbalances can be avoided without sacrificing the advantages of randomisation. Stratified randomisation is achieved by performing a separate randomisation procedure within each of two or more strata of participants (e.g., categories of age or baseline disease severity), ensuring that the numbers of participants receiving each intervention are closely balanced within each stratum. Stratification requires some form of restriction (e.g., blocking within strata) to be effective. The number of strata should be limited to avoid over-stratification [338]. Stratification by centre is common in multicentre trials.

Minimisation

Minimisation assures similar distribution of selected participant factors between study groups [334, 339]. Randomisation lists are not set up in advance. The first participant is truly randomly allocated; for each subsequent participant, the treatment allocation that minimises the imbalance on the selected factors between groups at that time is identified. That allocation may then be used, or a choice may be made at random with a heavy weighting in favour of the intervention that would minimise imbalance (for example, with a probability of 0.8) [340]. The use of a random component is generally preferable [341]. Minimisation has the advantage of creating small groups closely similar in terms of specific desirable participant characteristics at all stages of the trial.

 

Minimisation offers the only acceptable alternative to randomisation, and some have argued that it is superior [342]. Conversely, minimisation lacks the theoretical basis for eliminating bias on all known and unknown factors. Nevertheless, in general, trials that use minimisation are usually considered methodologically similar to randomised trials, even when a random element is not incorporated. For SPIRIT, minimisation is considered a restricted randomisation approach without any judgement as to whether it is superior or inferior to other restricted randomisation approaches.

Box 5 Need for a separate document to describe restricted randomisation

 

If some type of restricted randomisation approach is to be used, in particular blocked randomisation or minimisation, then knowledge of the specific details could lead to bias [343, 344]. For example, if the trial protocol for a two-arm, parallel group trial with a 1:1 allocation ratio states that blocked randomisation will be used and the block size will be 6, then trial implementers know that the intervention assignments will balance every 6 participants. Thus, if intervention assignments become known after assignment, knowing the block size will allow trial implementers to anticipate when equality of the sample sizes will arise. A sequence can be discerned from the pattern of past assignments and then some future assignments could be accurately predicted. For example, if part of a sequence contained two “As” and three “Bs”, trial implementers would know the last assignment in the sequence would be an “A”. If the first three assignments in a sequence contained three “As,” trial implementers would know the last three assignments in that sequence would be three “Bs.” Selection bias could result, regardless of the effectiveness of allocation concealment (Item 22).

This is mainly a problem in open-label trials where everyone becomes aware of the intervention after assignment. It can also be a problem in trials where everyone is supposedly blinded (masked), but the blinding is ineffective, or the intervention harms provide clues such that treatments can be guessed.

We recommend that trial investigators do not provide full details of a restricted randomisation scheme (including minimisation) in the trial protocol. Knowledge of these details might undermine randomisation by facilitating deciphering of the allocation sequence. Instead, this specific information should be provided in a separate document with restricted access. However, simple randomisation procedures could be reported in detail in the protocol because simple randomisation is perfectly unpredictable.

Summary of key elements to address

  • Type of randomisation: simple versus restricted (e.g., blocked); fixed versus adaptive (e.g., minimisation); and where relevant, the reasons for such choices

  • If applicable, factors (e.g., recruitment site, sex, disease stage) to be used for stratification, including categories and relevant cut-off boundaries

  • For restricted randomisation, aside from the above: all other details on restriction (including minimisation) should be provided in a separate document in order to reduce predictability of the random sequence

Logo: jointly funded by the UKRI Medical Research Council and the NIHR (National Institute for Health and Care Research)
University of Oxford logo
University of Toronto logo
The University of North Carolina at Chapel Hill logo
University of Southern Denmark (SDU) logo
University of Ottawa (uOttawa) logo
Université Paris Cité (UPC) logo

The 2025 update of SPIRIT and CONSORT, and this website, are funded by the MRC-NIHR: Better Methods, Better Research [MR/W020483/1]. The views expressed are those of the authors and not necessarily those of the NIHR, the MRC, or the Department of Health and Social Care.

bottom of page